Compare FGBI & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FGBI | ASRT |
|---|---|---|
| Founded | 1934 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.4M | 75.1M |
| IPO Year | N/A | 1997 |
| Metric | FGBI | ASRT |
|---|---|---|
| Price | $5.00 | $10.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 23.4K | ★ 369.3K |
| Earning Date | 01-29-2026 | 11-10-2025 |
| Dividend Yield | ★ 0.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $13,036,000.00 | ★ $137,354,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 9.22 |
| 52 Week Low | $4.31 | $0.51 |
| 52 Week High | $11.84 | $9.90 |
| Indicator | FGBI | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 44.31 | 98.14 |
| Support Level | $4.73 | $0.61 |
| Resistance Level | $5.24 | $0.75 |
| Average True Range (ATR) | 0.21 | 0.10 |
| MACD | 0.11 | 0.57 |
| Stochastic Oscillator | 73.40 | 93.97 |
First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana, through several banking facilities. The principal business activity of the company includes attracting deposits and investing it together with funds generated from operations and borrowings insecurities and in lending activities to serve the credit needs of its customer base. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and to a lesser extent, consumer and multifamily loans.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.